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- Abstract-  
Major global and national vaccine allocation guidelines urge planners to allocate vaccines in 
ways that recognize, and ideally reduce, existing societal inequities within countries.  However, 
allocation plans of the US will be determined individually  by each of the CDC’s 64 
jurisdictions (states, the District of Columbia, five cities, and territories). We analyzed whether 
jurisdictions have incorporated novel approaches to reduce inequity, based on plans published by 
the CDC in early November 2020 (63 summaries [98% of all jurisdictions] and 47 full guidance 
documents [73% of all, including all 50 states]).    
Eighteen states adopted a novel proposal to use a disadvantage index to allocate vaccines 
more equitably, for five types of equity goals: 1) to prioritize disadvantaged groups directly, 2) to 
define priority groups in phased systems, 3) to plan tailored outreach and communication, 4) to 
plan the location of dispensing sites and 5) to monitor uptake. Yet just over a third of all states, 
and only half of the 16 states with the largest shares of disadvantaged populations—where 
reducing inequity would be most urgent—pursue such goals.  
While allocation frameworks are still evolving, the plans we analyzed mark important 
historical and practical benchmarks, and could become firm policy when COVID-19 vaccines 
are authorized and delivered. Vaccine roll-out poses unprecedented logistical and practical 
challenges.  To minimize the risk that ethics and social justice falls by the wayside in the busy 
months to come, planners at the federal, state and local levels should carefully consider on what 
grounds they decline to adopt equity measures that other planners deem important and feasible 
for defining priority populations, designing allocation quotas, and just as critical, enabling, and 
monitoring, uptake.    
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Introduction 
When a Covind-19 vaccine becomes available, all nations will face scarcity for months, with 
greatest scarcity in lower-income countries. In the United States, recommendations from the 
Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization 
Practice (ACIP) will formally guide which population groups should receive safe and effective 
Covid-19 vaccines. However, allocations will ultimately be determined by the CDC’s 64 
immunization grantees (comprising 50 states, the District of Columbia, 5 large cities, and 8 
territories: referred to below collectively as jurisdictions).  The CDC requested its jurisdictions to 
provide their plans by October 31, and it posted 63 summaries on November 8.1  We analyzed 
these plans in short- and long-form to understand to what extent they reflected important 
commitments to allocate vaccines in ways that reduce inequities and promote social justice.   
Covid-19 vaccine allocation relates to two main processes, providing available doses to 
jurisdictions according to their population or some other metric,2 and then, within jurisdictions, 
to specific populations in meaningful sequence.  Allocation frameworks seek to integrate a 
multitude of factors, such as saving the most lives and limiting the spread of infections, and are 
typically risk-based.  Figure 1 shows how the ACIP’s plan (including vote Dec 1, 2020 on phase 
1a) compares to one proposed earlier by the National Academies of Science, Engineering and 
Medicine (NASEM),3 a group tasked by the Centers of Disease Control and Prevention and the 
National Institutes of Health with assisting ACIP to develop equitable allocation guidance. 
Figure 1: Priority groups under NASEM and ACIP frameworks 
First144m people in the first 10 NASEM priority groups, accounting for overlap (note: 
ACIP framework still evolving, showing 1/multiple options. Depiction: Ariadne Labs) 
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Planning allocation across and within states presents unprecedented challenges and requires 
strong vaccine infrastructure, including human resources and data systems. In addition to a 
significant number of unknowns regarding the characteristics of vaccines, such as their longer-
term effectiveness; capacity to prevent transmission as opposed to mainly preventing disease; and 
adverse-effect profiles, there are complex logistics centered around shipping and distribution; 
establishing handling and storage protocols; and ensuring administration and verification of 
follow-up second doses (where required) and overall vaccine coverage.  Countless tradeoffs will 
likely need to be made among higher level aspirations regarding efficiency and equity, real-world 
logistical and pragmatic constraints, and established pathways in which federal, state and local 
health departments operate.4  In the overall rush to control the pandemic, implementation can 
be as important as a vaccines’ efficacy.5 Even the most effective vaccines cannot curb SARS-
CoV-2 unless a sizable portion of the population is immunized, estimated at over 90 percent. A 
central question is to what extent potentially frantic implementation will align—or stand in 
conflict—with commitments to mitigate existing societal inequities, particularly those affecting 
economically worse-off racial and ethnic minorities.  
ACIP’s overarching ethical values for allocating initial supplies of Covid-19 vaccines note 
that allocation strategies “should aim to both reduce existing disparities and to not create new 
disparities”.6 The latter statement echoes a similar one from an earlier publication of ACIP’S 
scientific and ethical principles, which explained that to “address the disproportionate burden of 
COVID-19 disease in some racial/ethnic minority groups […] strategies for implementation 
[should] reduce, rather than increase, health disparities in each phase of vaccine distribution”.7 
This emphasis is also found in early academic commentary on the subject8 and influential high-
level policy advice by the NASEM,3 as well as of the World Health Organization’s WHO 
Strategic Advisory Group of Experts on immunization (SAGE).9  
As figure 1 shows, to some extent, risk-based allocation frameworks such as the one 
proposed by NASEM or ACIP already address inequities by, for example, proposing to offer 
vaccines to people with multiple co-morbidities before otherwise healthy people. Due to the 
social determinants of health, economically worse-off populations are generally less healthy.10-12 
Therefore, a risk-based approach will allocate more vaccine sooner to economically worse-off 
populations.  Likewise, since an implication of structural racism is that minorities face reduced 
economic mobility and account for larger shares of the economically worse-off,13-15 such an 
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approach suggests that minority populations would be offered vaccines sooner.  Similarly, 
offering vaccines to essential workers earlier can have this consequence, as minorities comprise a 
larger share of this workforce.3,6 
Importantly, however, NASEM also recommended the use of an additional measure. 
Within each phase of allocation, and in “each population group, vaccine access should be 
prioritized for geographic areas identified through CDC’s Social Vulnerability Index [SVI] or 
another more specific index.”2 An index such as SVI is tied to a geographic area, down to the 
level of neighborhoods, and captures their relative average advantage and disadvantage through 
a set of variables that go beyond income alone, and integrate, for example, educational 
attainment and housing quality16 (and in the case of SVI also explicitly race and ethnicity).17 
Such indices can therefore capture population groups for whom the protection offered by 
vaccines is both more necessary and more valuable, as they are typically more dependent on 
regular income, less able to socially distance, and more likely to contract and spread the 
infection. In addition to public health and economic considerations, disadvantage indices matters 
ethically, and can promote restorative justice.8,14,18 The NASEM notes that measures such as the 
SVI incorporate “the variables that the committee believes are most linked to the 
disproportionate impact of COVID-19 on people of color and other vulnerable populations.”  
Concretely, the NASEM recommends setting aside 10% of federally available vaccines to be 
added to the allocations that worse-off groups would otherwise be offered, proportionate to 
population,19 under its risk-based framework. Complementing this effort, jurisdictions should 
furthermore “ensure that special efforts are made to deliver vaccine to residents of high-
vulnerability areas (defined as the 25 percent highest in the state).”3 CDC staffers noted that the 
SVI could be integrated into Tiberius, a newly developed software system intended to assist states 
with vaccine allocation.16  To ascertain the extent to which emerging allocation guidance 
incorporates statistical measures of disadvantage to reduce inequities, we therefore analyzed 
jurisdictions’ initial frameworks.  
 
Methods  
We obtained summaries of all jurisdictions’ allocation plans published by November 8 on the 
CDC’s dedicated website.1  Where a document linked to full guidance, we included it in the 
analysis, and additionally obtained full plans by searching jurisdictions’ health department 
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websites (Nov 7-14; archived copies available from the authors).  Plans were analyzed using a 
seven-item extraction tool (see Appendix 1) conceptualized by HS, MAW and LG and refined in 
discussion with AS and RW, eliciting:  
1. Whether jurisdictions intended to use an index of disadvantage for prioritization of worse-off 
population groups or other purposes;  
2. Insofar as prioritization of worse-off is planned, what share of what population should be 
prioritized, and to what extent;  
3. Whether plans envisaged the use of the newly developed Tiberius platform. 
Two authors (AD and HW) each analyzed and tabulated half of all plans, and another (ES) 
verified all data entry.  HS, ES, HW, and AD resolved any differences in data capture, which 
were marginal, given the simplicity of the extraction tool. 
 
Results 
We obtained a total of 63 summaries (98.4% of all jurisdictions) and 47 full guidance documents 
(73.4% of all jurisdictions, including all states).  Table 1 and Figure 2 summarize the findings. 
Eighteen jurisdictions (all states, none are cities) refer to the SVI; California developed its own 
metric.  A range of distinct uses of disadvantage measures emerged from the data, which we 
describe in more detail below. Twenty-four jurisdictions plan on using Tiberius (which may 
include prioritized allocations to worse-off areas, as captured by the SVI), including 15 that do 
not otherwise indicate that they intend to use SVI for other purposes that might benefit worse-off 
groups more.  
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Figure 2: Jurisdictions’ use of statistical measures of disadvantage for prioritizing vaccine 
allocation, use of Tiberius allocation software system – geographical depiction 
 
Note: In states shown in bold, more than 25% of the population are in the US’ worse-off quartile, as measured on 
the SVI applied nationally. See Appendix 2. 
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Table 1: Jurisdictions’ use of statistical measures of disadvantage for prioritizing vaccine allocation, use of Tiberius allocation software system 
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Among the 18 states that refer to the SVI, five different purposes can be distinguished (some 
jurisdictions indicate the intention to pursue more than a single goal; see Table 2 for an overview, 
and Appendix 1 for the full extracted data for further context).  
In direct alignment with NASEM’s recommendation, seven states indicate expressly that 
measures of disadvantage can help address social injustice in allocation planning (CA, IN, ND, 
NY, OH, VT, TN). The most specific articulation is found in Tennessee, which mirrors 
NASEM’s approach at the state level and proposes to reserve 10% of its allocation for high SVI 
areas. Eighty-five percent would be allocated to counties by population, and 5% “equitably.”   
Ten states plan to use the SVI to identify priority populations (AL, FL, MA, NM, NY, 
OR, RI, SC, VT, WA). North Dakota contemplates using the SVI for a particular population 
group (to “ensure equity in the number of doses Tribal healthcare providers receive”), and NY 
notes the goal of identifying “which geographic areas of the state may derive a greater public 
health benefit to receiving early vaccine. This may include areas with higher historical burden of 
disease or areas that have the highest prevalence of COVID-19.”  
Four states (AZ, NJ, VT, WA) plan to use the SVI for purposes distinct from identifying 
priority groups, or determining the quantity of vaccines offered to a group. These states note the  
SVI’s utility for promoting uptake, for example, planning locations of dispensing sites (NJ) or 
outreach or communication strategies (AZ, VT, WA).   
Finally, Ohio intends to use the SVI “both a priori when deciding geographic distribution 
of vaccines, and post-hoc to ensure that state’s goals to protect the most-at-risk and vulnerable 
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Table 2: Central verbatim sections illuminating states’ approach to drawing on statistical measures of 
disadvantage in allocating vaccines in situations of scarcity and non-scarcity   
(Note: regular font indicates that the text comes from the summary provided to CDC, italics that the text is found in the 
states’ full guidance) 
Prioritize worse off using SVI 
CA Identifying populations and communities that have been disproportionately impacted by COVID-19 and has 
developed a health equity metric to help guide continuing efforts to address disparities. 
The equity metric is designed to reduce cases in the most disproportionately impacted communities, as defined by the census tracts in the 
lowest quartile of the Healthy Places Index within larger counties, and as defined by population and geography by the local health 
departments in smaller counties (where census tracts cannot be used). 
IN The CDC Social Vulnerability Index will be reviewed during the allocation process and applied if there is a limited vaccine during 
this phase. A document that identifies the SVI and estimated counts for comorbid conditions per county will assist in targeted 
allocation, distribution, and communication during this phase. Counties with higher SVIs may receive an increased allocation per 
population.  
LA In each population group, OPH will use CDC’s Social Vulnerability Index (SVI) or another more specific index, as needed to 
prioritize for geographical areas for vaccine access. 
MI MDHHS Division of Immunization will initially allocate COVID19 vaccine to hospitals and health systems and 
Local Health Departments (LHD) that can manage a large allocation of Vaccine A for administration to health 
care providers. Thereafter, allocations will be made to each of the health jurisdictions within Michigan for 
prioritization to community providers who have the ability to vaccinate the priority groups. Allocations are 
determined based on several factors including the social vulnerability index and population. 
After initial allocations to hospitals, allocations will be made to each of the 45 health jurisdictions based on several factors including 
the social vulnerability index and population. LHDs will then use the relationships they have built with the community to allocate out 
additional amounts of vaccine to the providers in their community who are able to reach the vulnerable populations. 
ND The ND Advisory Committee on COVID-19 Vaccine Ethics may choose to utilize CDC’s vulnerability index when allocating 
vaccine, which may ensure equity in the number of doses Tribal healthcare providers receive. 
OH In addition, vaccine administration will be assessed using the CDC’s Social Vulnerability Index both a priori when deciding 
geographic distribution of vaccines and post-hoc to ensure that state’s goals to protect the most-at-risk and vulnerable Ohioans are 
upheld. 
TN After careful review of the CDC Playbook and the National Academies’ of Sciences, Engineering and Medicine’s Framework for 
Equitable Allocation of COVID-19 Vaccine and discussion with the Stakeholder Group, TDH leadership, and the Unified 
Command Group, the following structure has been adopted for the allocation and prioritization of COVID-19 vaccines: 
Allocation: 
• Ten percent of the State’s allocation of COVID-19 vaccines will be reserved by the State for use in targeted areas with high Social 
Vulnerability Index (SVI) values. 
• Five percent of the State’s allocation of COVID-19 vaccines will be distributed equitably among all 95 counties. 
• Eighty-five percent of the State’s allocation of COVID-19 vaccines will be distributed among all 95 counties based upon their 
populations. 
Define priority groups, possibly also prioritize 
AL The Data Group will use all the available databases used for COVID-19 surveillance (including the Social 
Vulnerabilities Index), and CDC provided databases to identify, estimate the numbers, and where they are 
located. 
FL The Department’s Office of Minority Health and Health Equity has been engaged in vaccination planning and 
existing networks and data will be utilized to inform these efforts. Social vulnerability indexes are available in 
GIS platforms and communities with health disparities have been identified 
MA …will identify and prioritize critical populations for vaccination following federal guidance . . In addition, The 
Office of Population Health (OPH) manages the contract with Boston University School of Public Health (BUSPH) for Social 
Vulnerability Index (SVI) analysis and related mapping support. Within OPH, the Office of Health Equity (OHE) works to 
address social determinants so all Massachusetts residents can attain their full health potential. […]using the CDC’s Social 
Vulnerability Index to assess the interaction of these forces [occupation, housing type, school enrollment, race/ethnicity, primary 
language, health care access, co-morbidities, socioeconomic factors ] on the likelihood members of critical populations will accept, seek, 
and be able to access COVID-19 vaccine. 
Working with our collaborative Social Vulnerability Index (SVI) analytic and mapping partner, the Boston University School of 
Public Health, maintain superior ability to map these workforce resources at a granular level to inform planning.  
NM NMDOH will also use numerous data sources, including the CDC’s Social Vulnerability Index to identify 
populations at highest risk. 
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NY Once the vaccine is first approved for use, New York State will use up-to-date data to determine which geographic areas of the state 
may derive a greater public health benefit to receiving early vaccine. This may include areas with higher historical burden of disease or 
areas that have the highest prevalence of COVID-19. In addition, individual factors for hospitals and nursing homes will be 
considered including cases per facility in prior 14 days, and vulnerability index of population served. New York will also consider 
whether the vaccine can be used effectively as a potential outbreak interruption strategy and if so, what the criteria will be. 
OR Options for mapping population data (including Tiberius, Tableau and ArcGIS) are actively being explored in conjunction with 
mapping of CDC’s Social Vulnerability Index (SVI) to identify overlap and potential areas of greatest need. 
RI The MV Workgroup will leverage a range of data sources to estimate numbers of critical populations …. Data sources consulted in 
the process of quantifying and locating members of critical populations include (though are not limited to): 
- Federal agency data to CMS; - CDC - Social Vulnerability Index 
SC DHEC is closely monitoring guidance put forth by the CDC's Advisory Committee on Immunization Practices (ACIP), the National 
Institutes of Health, and the National Academies of Sciences, Engineering, and Medicine (NASEM) regarding identified populations 
of focus for COVID-19 vaccination. Other resources include: 
• CDC's Social Vulnerability Index, which accounts for natural and human-caused disasters and disease outbreaks.  
VT The Immunization Program will work closely with all COVID-19 vaccination providers and target settings to 
ensure equitable access to the COVID-19 vaccine. Vaccine allocation will be based on population data, with 
attention to critical populations. Vaccine administration data from the Immunization Registry will be monitored 
and reviewed by geographic location. Vaccine doses administered by enrolled sites will also be monitored and 
redistribution will be required. The Immunization Program is collaborating with the Health Operations Center’s 
Health Equity and Community Engagement Team to ensure access for people who are disproportionately 
affected by COVID-19, including Black, Indigenous and people of color. GIS mapping and Social Vulnerability 
Indices will be employed to identify areas with limited access and direct distribution efforts. 
WA The use of social vulnerability indexes and maps will also inform how critical populations and sub-populations 
can be reached equitably and will inform allocation decisions under supply constraints. We will use tools such as 
Washington Tracking Network Information and CDC Social Vulnerability Index to identify Census tracts in 
Washington that have higher health inequities overall and to map other relevant social determinants of health, 
such as overcrowded housing, poverty, disability, or health insurance coverage. 
Plan outreach/communication to ensure uptake (during scarcity or after) 
AZ …allocate vaccine for higher-risk individuals, health care professionals, and other essential workers as 
recommended by VAPAC.  
There may be areas with limited providers, a high social vulnerability index (SVI), vaccine hesitancy or other 
factors that lead to lower vaccine uptake. In these areas, ADHS plans to work with local partners to develop 
targeted messaging and mobile POD vaccination strategies to encourage vaccination 
…ADHS will utilize the SVI to identify communities that may need enhanced support before, during and after disasters. 
VT The Immunization Program will work closely with all COVID-19 vaccination providers and target settings to 
ensure equitable access to the COVID-19 vaccine. Vaccine allocation will be based on population data, with 
attention to critical populations. Vaccine administration data from the Immunization Registry will be monitored 
and reviewed by geographic location. Vaccine doses administered by enrolled sites will also be monitored and 
redistribution will be required. The Immunization Program is collaborating with the Health Operations Center’s 
Health Equity and Community Engagement Team to ensure access for people who are disproportionately 
affected by COVID-19, including Black, Indigenous and people of color. GIS mapping and Social Vulnerability 
Indices will be employed to identify areas with limited access and direct distribution efforts. 
WA The use of social vulnerability indexes and maps will also inform how critical populations and sub-populations can be reached 
equitably and will inform allocation decisions under supply constraints. We will use tools such as Washington Tracking Network 
Information and CDC Social Vulnerability Index to identify Census tracts in Washington that have higher health inequities overall 
and to map other relevant social determinants of health, such as overcrowded housing, poverty, disability, or health insurance coverage.  
Plan dispensing sites 
NJ Social Vulnerability Index (SVI)3 review to determine location of PODS [points of dispensing] 
Monitor uptake 
OH In addition, vaccine administration will be assessed using the CDC’s Social Vulnerability Index both a priori when deciding 
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Limitations and Discussion  
Jurisdictions were asked to publish allocation plans under an extremely tight schedule with just 
30 days between the official request and the deadline. While 63 provided summaries at the time 
of CDC’s publication, and fuller allocations plans were available for all states, they were not 
available concurrently for 16 jurisdictions. Many aspects regarding implementation that affect 
these plans, such as cold-storage needs, are only now becoming concrete, as the Food and Drug 
Administration determines which vaccines to authorize.5  In this sense, currently available plans 
offer only a snap-shot of evolving guidance.  Moreover, using a statistical measure of 
disadvantage is not the only way of reducing disparities, and not every intended use might have 
been noted in the initial allocation plans. At the same time, the NASEM’s recommendation that 
such a measure is called for to address Covid-19’s unjust impact—and that it should be used in 
addition to a risk-based framework with specific phases and specific subpopulations—was 
patently clear. Likewise, every jurisdiction planner was likely aware of the vastly disparate Covid-
19 impacts across racial and ethnic groups, in terms of unemployment, hospitalizations and 
deaths,18,20 and the concurrent national reckoning with racial justice, which also prompted the 
NASEM’s proposal. In this regard, the initial plans also represent an important historical 
benchmark, offering practical templates as well as a baseline measure of how pressing the need to 
reduce inequities and promote social justice is perceived to be, in relation to other important 
priorities.   
Four main themes emerged from the findings:  a) variation in the adoption of SVI and 
related measures, b) the degree of clarity about the likely impact of such measures on different 
dimensions of disparities, c) plans for the uptake of the Tiberius software, and d) the importance 
of disparate impact monitoring.   
A little over a third of states engaged directly with the novel proposal to utilize statistical 
measures of disadvantage to address social justice.  Among the 16 states that have more than 
25% of their population falling under the worst-off SVI quartile nationwide (see Appendix 2), 
half (n=8) plan on using the SVI: two with the goal of directly prioritizing worse-off groups (CA, 
LA), five to capture priority populations (and possibly prioritize further; AL, FL, NM, NY, SC), 
and one to draw on SVI for designing outreach/communication strategies once scarcity ends 
(AZ). Among the six jurisdictions with more than 30% worse-off (NM, DC, CA, NY, MS, TX), 
only two (CA, NY) plan on using the SVI, and four signal no such express intention at this point.   
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To reiterate, the use of a disadvantage index is not the only way in which equity could be 
addressed. We do not mean to suggest that the data presented here necessarily cast doubt on the 
commitments to equitable vaccine allocation of jurisdictions that currently do not indicate using 
such an index. But scrutiny of their efforts to explore—and more importantly implement and 
monitor—ways of allocating vaccines in ways that reduce inequities will likely increase. Note, for 
example, that even if all states were to set aside a 10% reserve of their allotted vaccines as 
additional amounts for those in the worst-off quartiles, under the NASEM framework, worse-off 
minorities would be offered vaccines below their population share until the beginning of phase 3, 
with the exception of the very first phase (see figure 1, Appendix 2, analogous simulation for the 
final ACIP framework ongoing).2 
The extent to which a disadvantage index will directly shape social justice-based 
prioritization is essential to understand even if at this point it is somewhat unclear. However, the 
state of Tennessee stands out in its clarity regarding the planned increases in the numbers of 
courses reserved for worse-off groups. The state proposes to reserve 10% of its allocation for high 
SVI areas (in addition to what these areas would receive based on population), although it would 
still need to be specified what population segment would be offered the extra doses—given the 
direct alignment with the NASEM’s overall recommendation, likely the state’s worst-off quartile 
(alternatively, a more continuous approach could avoid inequities between, for example two 
census tracts that are marginally below and marginally above the 25% threshold).  Tennessee 
also highlights the need to address intra-state variations by allocating 85% proportionate to 
population, but reserving a further 5% “equitably” (which, presumably, would be based on a 
measure like SVI, poverty measures, or another standard that operationalizes a sense of need).   
An important use of the SVI relates to the expression among vaccine workers that 
“Vaccines don’t save lives. Vaccinations save lives.”21  In the present context, this means that 
grouping worse-off populations in higher priority groups, or setting aside larger shares of vaccines 
alone, can be meaningless for reducing inequity if these steps are not matched with genuine 
efforts to ensure populations are also willing and able to accept vaccines. Outreach and effective 
communication are even more crucial if states make no additional efforts at prioritizing worse-off 
groups across phases or through larger allocated amounts. Yet, currently, only 4 states (AZ, NJ, 
VT, WA) describe that they plan to use the SVI for planning the location of dispensing sites, or 
communication and outreach efforts. None of the states with more than 30% of its population 
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falling under the nationally worst-off quartile plan such uses, and only one the 16 states with 
more than 25% worse-off does so (AZ; while the state recognizes the SVI’s utility in this regard, it 
currently indicates no plans to use it for any other purpose).  
Using a rigorous measure of disadvantage for promoting uptake is of great importance in 
view of the overall policy that jurisdictions will only receive new vaccine allocations once already 
received batches have been distributed.22  While entirely reasonable in its motivation to minimize 
wastage, an unintended consequence of this policy could be that jurisdictions might prioritize 
regions where uptake is swift and virtually guaranteed, and conversely, might deprioritize 
locations with real or anticipated lower uptake.   
Such an outcome would recreate the kind of dynamics that the NASEM sought to 
address with its proposal to use the SVI to mitigate the consequences of structural racism. 
Interpreting low vaccine uptake in, for example, communities with predominantly Black 
populations as expressing that these groups might simply not be interested in vaccines would be 
based on an overly simplistic understanding of autonomy. In planning outreach and 
communication activities, history matters.  It is therefore crucial to be aware that rather than 
simply indicating a personal preference, vaccine hesitancy has different reasons that require 
different responses,23 and can moreover be an entirely rational expression of lacking trust in the 
healthcare system and in government. Egregious historical ethical violations such as the Tuskegee 
study cast a long shadow in the collective memory of, particularly, Black communities, and 
ongoing experiences of structural racism in healthcare and beyond likewise undermine trust.24-26 
States with larger shares of worse-off communities of color and others not engaged with the 
healthcare system would therefore be well advised to explore similar uses of the SVI as intended 
by AZ, NJ, VT, and WA, particularly given that the incentive structures governing the 
deployment of new tranches of vaccines currently favor prioritizing allocations to geographic 
areas with the swiftest uptake.   
On a practical note (with normative implications), approximately one-third (n=24) of 
jurisdictions indicate they plan to use the Tiberius Platform, including 15 that do not signal any 
other use of the SVI.  This trend also matters normatively. Uniform adoption of a centralized 
platform to inform state plans can have advantages in, for example, consistent implementation of 
SVI-based prioritization, and transparency around the near-real-time data being used for 
decisions (e.g., re-distribution of doses at the local level). It might be puzzling why about two-
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thirds of jurisdictions turn down the offer of a free platform with defined application. Anecdotal 
evidence suggests that novelty; concerns around the opacity of data integration; and about 
alignment of data representation with state-level data sets are part of the explanation. Improving 
transparency appears a desirable first step towards greater efficiency and operational 
effectiveness, and, possibly, more uniform use of adjusting allocations with disadvantage 
measures.     
Finally—and directly related to the above points regarding variations in adopting SVI; 
questions about the impact that different types of adoptions will have; and use of Tiberius—
planners in Ohio ought to be commended for expressly planning to use a disadvantage index not 
only for allocation purposes, but also for monitoring uptake.  Such initiatives—for example, by 
assessing coverage rates by SVI deciles—can support disparate impact monitoring, a legal 
concept focused on determining whether policies negatively affect a protected group, even if they 
do not have that express intention, or directly use information about that group.25-27  Ideally, 
given the salience of the goal of reducing inequities, the extent to which vaccines reach worse-off 
groups would be monitored at the federal level (and would appear to be feasible to implement, 
were a platform such as Tiberius more acceptable to jurisdictions). However, pragmatically, 
disparate impact monitoring is best conducted—and planned for, from the outset—at the state 
level, for it is here that vaccine redistributions, along with intensifications of outreach, 
communication or concentration of dispensing sites efforts, would need to be adjusted. 
 
Conclusion 
The nation faces an unprecedented logistical and social justice challenge in allocating vaccines 
under scarcity in the next half year or so. (At the global level, we anticipate scarcity for much 
longer periods of time, especially in low- and middle-income countries). Overall, the better-off 
white majority will be able to live and work socially distanced for a few months more with 
reasonable inconvenience. Unfortunately, the same cannot be said for the most disadvantaged 
communities, including, particularly, racial and ethnic minorities, who are a greater risk, and for 
whom a vaccine is far more important.  Jurisdictions should explore to the fullest extent the 
potential of using statistical measures of disadvantage, alongside other options, to allocate 
vaccines equitably.3,8  
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The tasks at hand are urgent and complex. But we are also at a point where social justice must 
become central, rather than continue to be peripheral.  There is still time for jurisdiction 
planners to play a direct role in changing the course of a troubling historical trajectory. 
Establishing allocation frameworks that increase the chances of more disadvantaged 
communities—and particularly those of color—to be offered a vaccine can help to reduce 
inequity, and can be one way of mitigating the consequences of past, and in many ways still 
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Appendix 1 
 
Complete data extraction tool: References to the use of statistical measures of disadvantage, and the Tiberius platform, 
in the CDC’s jurisdictions initial allocation frameworks (based on a) summaries of all jurisdictions’ allocation plans 
published by November 8 on the CDC’s dedicated website,1 and b) full versions, which were either obtained website 
links within the short version, or obtained through additional searches on jurisdictions’ health department websites 
(Nov 7-14; archived copies available from the authors).   
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Appendix 2 – Data on quantifying shares of worse-off populations and the impact 
of statistical measures of disadvantage to adjust allocations 
 
At the time the NASEM recommended setting aside a 10% national reserve to be allocated to 
worse-off populations as captured under SVI, it was unclear what quantitative impact this would 
have in terms of the numbers of doses offered to these communities. To quantify this, we 
simulated using SVI along a modified version of the index that reduced legal challenges, and 
another index that likewise reduces this risk (the Area Deprivation Index, ADI).1  The figure 
below shows on the left-hand side the consequences of setting aside 10% at the state-level (the  
more realistic approach, see the example of Tennessee, noted in the manuscript) of the amount 
allocated to states based on population and adding this in addition to the share that a states’ 
worse-off quartile as captured on the respective index would receive.  The right-hand side shows 
the consequences of doubling this amount to 20%, which can also give a rough2 idea of what a 
combined 10% reserve at the national level, and at the state level would mean.  
The share of the worse-off quartile among minority populations that would be offered vaccines 
under the unadjusted NASEM framework in shown in the gray line. In the initial phase, all 
indices would offer worse-off minorities vaccines above their population share, even though in 
the case of the unadjusted NASEM framework the margin is slim, and considerably higher on 
the different indices. Around half-way through phase 1, using only the state-level 10% reserve 
(left-hand side illustration), on all scenarios the  share of offered vaccines drops below the 
population share, while increasing the reserve size to 20% leads to offers that are consistently 
above the population share.  Note also the shares of covid-related deaths (crude and age-
adjusted) of all minority populations collectively, that are shown for context on the vertical axis. 
Further, note that the standardized assumptions made here set aside logistical complexities of 
implementation, that likely make it harder, rather than easier to reach worse-off groups. 
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The US’s states do not have equal shares of worse-off populations. Figure 1 shows what share of 
each state’s population falls into the nation’s worse-off quartile, varying from 36% (NM) to 12% 
(NH).3 In 16 ‘Increased Competition’ states, the worse-off group accounts for more than 25% of 
its population: allocating vaccine proportionate to population would increase scarcity for these 











2 In a subsequent study, we addressed the question of whether a 10% national reserve, or a 10% 
state-level reserve would be more beneficial, finding the former superior, but the latter still 
preferable over no adjustment, see:  Schmidt, Harald and Pathak, Parag A. and Williams, Michelle A. 
and Sonmez, Tayfun Oguz and Unver, Utku and Gostin, Lawrence O., Rationing safe and effective 
Covid-19 vaccines: allocating to states proportionate to population may undermine commitments to 
mitigating health disparities (November 12, 2020). Available at 
SSRN: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3729069    
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3 Schmidt, Harald and Pathak, Parag A. and Williams, Michelle A. and Sonmez, Tayfun Oguz and Unver, Utku 
and Gostin, Lawrence O., Rationing safe and effective Covid-19 vaccines: allocating to states proportionate to 
population may undermine commitments to mitigating health disparities (November 12, 2020). Available at 
SSRN: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3729069    
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